EHEmma Hazelwood

Emma Hazelwood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Hazelwood has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Causal Effects of Childhood BMI on Regional Fat Distribution in Adults: A Mendelian Randomisation and Proteomic Mediation Analysis

    by B Hayes, E Hazelwood, G Power, J Gilbody, Dj Pournaras, H Freisling, R Richmond, Ee Vincent

    Childhood obesity is a major global health concern, yet the long-term effects of early-life adiposity on adult fat distribution and underlying biological pathways remain poorly understood. In particular, it is unclear whether childhood BMI differentially influences specific adipose tissue depots and whether circulating proteins mediate these relationships. We conducted a Mendelian randomisation study using genetic instruments for childhood BMI across 12 timepoints from ages 3 to 18 years. Two-sample MR was applied to five MRI-derived adult fat depots (abdominal subcutaneous (ASAT), gluteofemoral (GFAT), visceral (VAT), liver, and pancreatic fat) in UK Biobank. We further implemented a two-step MR framework to assess whether 2,940 circulating plasma proteins (Olink) mediate observed associations, integrating temporal, statistical, and directional evidence across childhood. Genetically predicted higher childhood BMI from approximately age 7 years onwards was associated with increased ASAT and GFAT in adulthood, but showed little evidence of association with visceral, liver, or pancreatic fat, with effects persisting into adolescence. Two-step MR identified 140 proteins influenced by childhood BMI during a developmentally sensitive window, of which seven showed directionally consistent evidence of mediation. These proteins included ACAN, CCL7, and CLIC5 for abdominal subcutaneous fat, and CLIC5, BMP10, CLEC10A, KIT, and IGSF3 for gluteofemoral fat, highlighting partially distinct biological pathways across depots. Childhood BMI exerts depot-specific effects on adult fat distribution, particularly influencing subcutaneous adipose tissue. Circulating proteins provide evidence of potential mediating pathways, supporting the existence of developmentally sensitive biological mechanisms linking early-life adiposity to adult body composition. These findings underscore childhood as a critical period for shaping long-term adipose tissue distribution and highlight potential molecular targets for future intervention strategies. Author Summary: How much fat someone carries as a child can shape their health for decades, but where that fat ends up in the body as an adult may matter just as much as how much there is. Fat stored under the skin behaves very differently, biologically, from fat stored around internal organs or within the liver — and these different patterns are linked to different health risks later in life. In this study, we used genetic data to test whether having a higher body weight in childhood causally influences how fat is distributed across the body in adulthood, rather than simply relying on correlations that could be explained by other factors. We also looked at levels of specific proteins in the blood to see whether they might help explain this link — acting as a biological bridge between childhood body weight and where fat settles later in life. By pinpointing proteins that may carry this influence forward, we hope to shed light on the biological pathways connecting early-life body weight to long-term patterns of fat distribution, which could inform future research into prevention or intervention strategies. This work is part of a broader research programme investigating how body fat distribution relates to health outcomes across the life course.

  • Open Access

    Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis

    by Emma Hazelwood, Lucy J Goudswaard, Matthew A Lee, Marina Vabistsevits, Dimitri J Pournaras, Hermann Brenner, Daniel D Buchanan, Stephen B Gruber, Andrea Gsur, Li Li, et al.

    Introduction: There is convincing evidence that overall adiposity increases the risks of several cancers. Whether the distribution of adiposity plays a similar role is unclear. Methods: We used 2-sample Mendelian randomization (MR) to examine causal relationships of 5 adiposity distribution traits (abdominal subcutaneous adipose tissue (ASAT); visceral adipose tissue (VAT); gluteofemoral adipose tissue (GFAT); liver fat; and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, esophageal adenocarcinoma, and meningioma). Results: Sample size across all genome-wide association studies (GWAS) ranged from 8407 to 728 896 (median: 57 249). We found evidence that higher genetically predicted ASAT increased the risks of endometrial cancer, liver cancer, and esophageal adenocarcinoma (odds ratios (OR) and 95% confidence intervals (CI) per standard deviation (SD) higher ASAT = 1.79 (1.18 to 2.71), 3.83 (1.39 to 10.53), and 2.34 (1.15 to 4.78), respectively). Conversely, we found evidence that higher genetically predicted GFAT decreased the risks of breast cancer and meningioma (ORs and 95% CIs per SD higher genetically predicted GFAT = 0.77 (0.62 to 0.97) and 0.53 (0.32 to 0.90), respectively). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (ORs and 95% CIs per SD higher genetically predicted adiposity trait = 4.29 (1.41 to 13.07) and 4.09 (2.29 to 7.28), respectively). Discussion: Our analyses provide novel insights into the relationship between adiposity distribution and cancer risk. These insights highlight the potential importance of adipose tissue distribution alongside maintaining a healthy weight for cancer prevention.


  • Open Access

    Transcriptome-wide Mendelian randomization exploring dynamic CD4+ T cell gene expression in colorectal cancer development

    by Benedita Deslandes, Xueyan Wu, Matthew A Lee, Lucy J Goudswaard, Gareth W Jones, Andrea Gsur, Annika Lindblom, Shuji Ogino, Veronika Vymetalkova, Alicja Wolk, et al.

    Recent research suggests higher circulating lymphocyte counts may protect against colorectal cancer (CRC). However, the role of specific lymphocyte subtypes and activation states remain unclear. CD4+ T cells—a highly dynamic lymphocyte subtype—undergo gene expression changes upon activation that are critical to their effector function. Previous studies using bulk tissue have limited our understanding of their role in CRC risk to static associations. We applied Mendelian randomization (MR) and genetic colocalisation to evaluate causal relationships of gene expression on CRC risk across multiple CD4+ T cell subtypes and activation states. Genetic proxies were obtained from single-cell transcriptomic data, allowing us to investigate the causal effect of expression of 1,805 genes across CD4+ T cell activation states on CRC risk (78,473 cases; 107,143 controls). Analyses were stratified by CRC anatomical subsites and sex, with sensitivity analyses assessing whether the observed effect estimates were likely to be CD4+ T cell-specific. We identified 6 genes—FADS2, FHL3, HLA-DRB1, HLA-DRB5, RPL28, and TMEM258—with strong evidence for a causal role in CRC development (FDR-P < 0.05; colocalisation H4 > 0.8). Causal estimates varied by CD4+ T cell subtype, activation state, CRC subsite and sex. However, many of genetic proxies used to instrument gene expression in CD4+ T cells also act as eQTLs in other tissues, highlighting the challenges of using genetic proxies to instrument tissue-specific expression changes. We demonstrate the importance of capturing the dynamic nature of CD4+ T cells in understanding CRC risk, and prioritize genes for further investigation in cancer prevention.


  • Open Access

    Multi-tissue expression and splicing data prioritise anatomical subsite- and sex-specific colorectal cancer susceptibility genes

    by Emma Hazelwood, Daffodil M. Canson, Benedita Deslandes, Xuemin Wang, Pik Fang Kho, Danny Legge, Andrei-Emil Constantinescu, Matthew A. Lee, D. Timothy Bishop, Andrew T. Chan, et al.

    Genome-wide association studies have suggested numerous colorectal cancer (CRC) susceptibility genes, but their causality and therapeutic potential remain unclear. To prioritise causal associations between gene expression/splicing and CRC risk (52,775 cases; 45,940 controls), we perform a transcriptome-wide association study (TWAS) across six tissues with Mendelian randomisation and colocalisation, integrating sex- and anatomical subsite-specific analyses. Here we reveal 37 genes with robust causal links to CRC risk, ten of which have not previously been reported by TWAS. Most likely causal genes with evidence of cancer cell dependency show elevated expression linked to risk, suggesting therapeutic potential. Notably, SEMA4D, encoding a protein targeted by an investigational CRC therapy, emerges as a key risk gene. We also identify a female-specific association with CRC risk for CCM2 expression and subsite-specific associations, including LAMC1 with rectal cancer risk. These findings offer valuable insights into CRC molecular mechanisms and support promising therapeutic avenues.


  • Open Access

    Transcriptome-wide Mendelian randomisation exploring dynamic CD4+ T cell gene expression in colorectal cancer development

    by Benedita Deslandes, Xueyan Wu, Matthew A. Lee, Lucy J. Goudswaard, Gareth W. Jones, Andrea Gsur, Annika Lindblom, Shuji Ogino, Veronika Vymetalkova, Alicja Wolk, et al.

    Background: Recent research has identified a potential protective effect of higher numbers of circulating lymphocytes on colorectal cancer (CRC) development. However, the importance of different lymphocyte subtypes and activation states in CRC development and the biological pathways driving this relationship remain poorly understood and warrant further investigation. Specifically, CD4+ T cells – a highly dynamic lymphocyte subtype – undergo remodelling upon activation to induce the expression of genes critical for their effector function. Previous studies investigating their role in CRC risk have used bulk tissue, limiting our current understanding of the role of these cells to static, non-dynamic relationships only. Methods: Here, we combined two genetic epidemiological methods – Mendelian randomisation (MR) and genetic colocalisation – to evaluate evidence for causal relationships of gene expression on CRC risk across multiple CD4+ T cell subtypes and activation stage. Genetic proxies were obtained from single-cell transcriptomic data, allowing us to investigate the causal effect of expression of 1,805 genes across five CD4+ T cell activation states on CRC risk (78,473 cases; 107,143 controls). We repeated analyses stratified by CRC anatomical subsites and sex, and performed a sensitivity analysis to evaluate whether the observed effect estimates were likely to be CD4+ T cell-specific. Results: We identified six genes with evidence (FDR- P 0.8 in genetic colocalisation analyses) for a causal role of CD4+ T cell expression in CRC development – FADS2, FHL3, HLA-DRB1, HLA-DRB5, RPL28 , and TMEM258 . We observed differences in causal estimates of gene expression on CRC risk across different CD4+ T cell subtypes and activation timepoints, as well as CRC anatomical subsites and sex. However, our sensitivity analysis revealed that the genetic proxies used to instrument gene expression in CD4+ T cells also act as eQTLs in other tissues, highlighting the challenges of using genetic proxies to instrument tissue-specific expression changes. Conclusions: Our study demonstrates the importance of capturing the dynamic nature of CD4+ T cells in understanding disease risk, and prioritises genes for further investigation in cancer prevention research.


  • Open Access

    Adiposity distribution and risks of twelve obesity-related cancers: a Mendelian randomization analysis

    by Emma Hazelwood, Lucy J. Goudswaard, Matthew A. Lee, Marina Vabistsevits, Dimitri J. Pournaras, Hermann Brenner, Daniel D Buchanan, Stephen B Gruber, Andrea Gsur, Li Li, et al.

    Background: There is convincing evidence that overall adiposity (as measured by body mass index) increases the risks of several cancers. Whether there are similar relationships between these cancers and the distribution of adiposity is unclear. Methods: In the absence of well-powered individual studies we utilised two-sample Mendelian randomization (MR) to examine causal relationships of five adiposity distribution traits (abdominal subcutaneous adipose tissue; ASAT, visceral adipose tissue; VAT and gluteofemoral adipose tissue; GFAT, liver fat, and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, oesophageal adenocarcinoma, and meningioma) and cancer subtypes/subsites. We then used multivariable MR to investigate whether plausible molecular intermediates could potentially be mediating the relationships identified. We used the largest available GWAS from European populations for all traits (sample size across all GWAS ranged from 8,407 to 728,896 (median: 57,249); cancer GWAS ranged from 279 to 133,384 cases (median: 4,532) and 3,456 to 727,247 controls (median: 68,802)). Results: We found evidence that higher genetically predicted ASAT increased risks of endometrial cancer (inverse variance-weighted (IVW) odds ratio (IVW OR) per standard deviation (SD) higher genetically predicted ASAT = 1.79, 95% confidence interval (CI) = 1.18 to 2.71), liver cancer (IVW OR per SD higher genetically predicted ASAT = 3.83, 95% CI = 1.39 to 10.53) and oesophageal adenocarcinoma (IVW OR per SD higher genetically predicted ASAT = 2.34, 95% CI = 1.15 to 4.78). Conversely, we found evidence that higher genetically predicted GFAT decreased risks of breast cancer (IVW OR per SD higher genetically predicted GFAT= 0.77, 95% CI = 0.62 to 0.97) and meningioma (IVW OR per SD higher genetically predicted GFAT = 0.53, 95% CI = 0.32 to 0.90). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (IVW ORs per SD higher genetically predicted adiposity trait = 4.29 and 4.09, 95% CIs = 1.41 to 13.07 and 2.29 to 7.28, respectively). Multivariable MR analyses suggested that traits related to insulin signalling, sex hormones, and inflammation may play important roles in mediating the effects of adiposity distribution on obesity-related cancers. Conclusions: Our analyses provide novel insights into the variability of the effect of adiposity distribution on cancer risk, with respect to both adiposity trait and cancer type, which would not be possible in a conventional observational analysis given the lack of available samples with all required traits measured. These findings demonstrate that adipose tissue at different anatomical locations may have differential effects on adiposity-related molecular traits. These insights enhance our understanding of the complex relationship between adiposity and cancer risk and highlight the importance of adipose tissue distribution alongside maintaining a healthy weight overall for cancer prevention.

  • Open Access

    Table S3 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis

    by Emma Hazelwood, Catalina Lopez Manzano, Emma E. Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M. Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, et al.

    Power calculations for genetically predicted ghrelin and colorectal cancer risk

  • Open Access

    Data from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis

    by Emma Hazelwood, Catalina Lopez Manzano, Emma E. Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M. Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, et al.

    Background:Epidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis.Methods:Genetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied.Results:We found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81–1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer.Conclusions:Our study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite–stratified colorectal cancer risk.Impact:This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.

  • Open Access

    Table S2 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis

    by Emma Hazelwood, Catalina Lopez Manzano, Emma E. Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M. Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, et al.

    Cancer betas for the SNPs associated with plasma ghrelin

  • Open Access

    Table S1 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis

    by Emma Hazelwood, Catalina Lopez Manzano, Emma E. Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M. Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, et al.

    SNPs associated with plasma ghrelin